Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice

Journal of Gastroenterology

Volumn 41, Issue 3, 2006, Pages 231-239

  Matsuzaki, Yasushi ^a   Nagai, Daichi ^b   Ichimura, Eiji ^b   Goda, Rika ^b   Tomura, Arihiro ^b   Doi, Mikio ^c   Nishikawa, Kiyohiro ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

^c Ibaraki Prefectural Institute of Public Health   (Japan)

Author keywords

CYP1A2; Flutamide; Glutathione; Hepatotoxicity; Metabolism

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450 1A2; FLUTAMIDE; GLUTATHIONE;

ANIMAL; ARTICLE; BLOOD; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; LIVER CELL; LIVER DISEASE; LIVER MICROSOME; MALE; METABOLISM; MOUSE; MOUSE MUTANT; MOUSE STRAIN; PROSTATE TUMOR; RAT; SPRAGUE DAWLEY RAT; TRANSACTIVATION;

ALANINE TRANSAMINASE; AMINO ACIDS; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; CELLS, CULTURED; CYTOCHROME P-450 CYP1A2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUTAMIDE; GLUTATHIONE; HEPATOCYTES; LIVER DISEASES; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICROSOMES, LIVER; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS);

EID: 33645838033     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-005-1749-y     Document Type: Article

References (20)

1. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
2. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57:727-32.
3. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992;92:465-70.
4. Matsuzaki Y, Nishikawa K. Therapeutic options for drug induced liver injury: the efficacy of UDCA based on EBM. Nippon Shokakibyo Gakkai Zasshi 2003;100:659-66.
5. Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 1997;25:1298-303.
6. Watanabe N, Goda R, Irie T, Yamashita K. In vitro effects of fluoroquinolon anti-bacterial agents on flutamide metabolism in human liver microsomes. Jpn J Clin Pharmacol Ther 2001;32: 65-71.
7. Radwanski E, Perentesis G, Symchowicz S, Zampaglione N. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol 1989;29:554-8.
8. Asakawa N, Koyama M, Hashimoto Y, Yamashita K. Studies on the metabolic fate of flutamide (4): biliary excretion, enterohepatic circulation, absorption from gastro-intestinal tract, metabolism and drug-metabolizing enzymes induction in rats. Xenobio Metabol Dispos 1995;10:470-83.
9. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994;269:954-62.
10. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, et al. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochrome P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 1993;265:366- 72.
11. Ichimura E, Hara K, Matsuzaki Y, Doi M. Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats. Acta Hepatol Jpn 1999;40:227-34.
12. Nakagawa Y, Koyama M, Matsumoto M. Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 1999;45:821-6.
13. Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, et al. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 2002;5:128-31.
14. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, Gonzales FJ. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci U S A 1995;92:5134-8.
15. Nakano R, Haji M, Yanase T, Ogo A, Takayanagi R, Katsube T, et al. A single amino acid substitution (Met786→Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome. J Clin Endocrinol Metab 1992;74:1152-7.
16. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
18. Boyne AF, Ellman GL. A methodology for analysis of tissue sulfhydryl components. Anal Biochem 1972;46:639-53.
19. Neda K, Handa J, Yamaguchi T, Onikata S, Hayashi M, Nakamori K, et al. A single dose toxicity study of flutamide in rats and dogs. Pharmacometrics 1993;45:135-40.
20. Aizawa Y, Ikemoto I, Kishimoto K, Wada T, Yamazaki H, Ohishi Y, et al. Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol Cell Biochem 2003;252:149-56.